



Image

1646 \$

PATENT

Attorney Docket No.: 01017/37128C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Medlock et al.

Serial No.: 10/037,591

Filed: December 21, 2001


For: IL-17 Like Molecules and
Uses Thereof

Group Art Unit: 1646

Examiner: D. Jiang

) I hereby certify that this paper is being
) deposited with the United States Postal
) Service as first class mail, postage prepaid,
) in an envelope addressed to: Commissioner
) for Patents, Washington, DC 20231 on this
) date:

) March 26, 2004

) 

) Sharon M. Sintich, Ph.D.

) Reg. No.: 48,484

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97, AND 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the applicants call to the attention of the Examiner the enclosed documents, as listed on the attached Form SB08A, which may be considered material to the examination of the above-identified patent application.

In accordance with 37 C.F.R. § 1.97(e), each item of information contained in the supplemental information disclosure statement was first cited in the International Search Report from the United States Patent and Trademark Office (International Search Authority) in a counterpart PCT application (PCT/US02/40247).

03/30/2004 FFANAEIA 00000013 10037591

01 FC:1806

180.00 DP




Serial No.: 10/037,591

Attorney Docket No.: 01017/37128C

This Supplemental Information Disclosure Statement is being submitted after receipt of the first office action on the merits. Enclosed is our check for the fee (\$180.00) due under 37 CFR §1.97(c). The Patent Office is hereby authorized to charge any additional fees related to this statement fee to Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

By: 
Sharon M. Sintich, Ph.D.
Reg. No.: 48,484

March 26, 2004



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/037,591
				Filing Date	December 21, 2001
				First Named Inventor	Eugene Medlock
				Art Unit	1646
				Examiner Name	D. Jiang
Sheet	1	of	1	Attorney Docket Number	01017/37128C

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		
	B9	WO 00/42187	July 20, 2000	Schering Corporation

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	C1	LEE <i>et al.</i> , "IL-17E, a Novel Proinflammatory Ligand for the IL17 Receptor Homolog IL-17Rh1," <i>Journal of Biological Chemistry</i> , 276:1660-1664 (2001)
	C2	MARRA <i>et al.</i> , Database EST, Accession Number W88186, September 12, 1996
	C3	International Search Report, PCT/US02/40247, United States as Searching Authority.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.